Pfizer CEO Albert Bourla speaks in the Oval Office on Sept. 30, 2025, as (L-R) Secretary of Health and Human Services Robert F. Kennedy Jr., Administrator for the Centers for Medicare and Medicaid Services Mehmet Oz, and President Donald Trump look on. Win McNamee/Getty Images
Sixteen drugmakers have entered into or are negotiating confidential pricing deals with the Trump administration. Apart from the broad strokes laid out in public announcements, most details remain unknown.
President Donald Trump’s aim in making the deals is to correct the longstanding practice by pharmaceutical companies of charging Americans about three times more for prescription medications than those in other countries.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.